Notably, about 62% of Groww's broking revenue in FY25 came from the F&O segment — though this dependence is declining as the business matures and as multi-product initiatives ramp up, the risk remains ...

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first 'off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the ...